Chordia Therapeutics Inc. (JP:190A) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Chordia Therapeutics Inc. has released the transcript of its earnings briefing for the fiscal year ended August 2024, aiming to enhance transparency and investor understanding. The company is actively developing cancer therapies, with its lead candidate CTX-712 undergoing Phase 1/2 clinical trials in the US.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.